Loree JM, Titmuss E, Topham JT, Kennecke HF, et al. Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial. Clin Cancer Res 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268.
PMID: 38727700